Search

Displaying results 2811 - 2820 of 10000 in total
  1. Drug

    Dronabinol

    go.drugbank.com/drugs/DB00470
    ApprovedIllicitInvestigational

    CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function [A32676]. … Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting

    Categories: Analgesics, Non-Narcotic
  2. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc … . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).

  3. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    [A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with … The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years.

  4. Drug

    Trimetrexate

    go.drugbank.com/drugs/DB01157
    Approved

    It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect.

  5. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    Linzagolix is a non-peptide, selective antagonist of the gonadotropin-releasing hormone (GnRH) receptor. … [A253667] Linzagolix was approved for use in the European Union in June 2022 for the management of symptoms caused by uterine fibroids.[L43627]

  6. Drug

    Remoxipride

    go.drugbank.com/drugs/DB00409
    ApprovedWithdrawn

    [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512] … Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors.

  7. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.

    Categories: Agents Acting on the Renin-Angiotensin System
  8. Drug

    Chloramphenicol succinate

    go.drugbank.com/drugs/DB07565
    Approved

    [L14174] Chloramphenicol succinate was granted FDA approval on 20 February 1959.[L12711] … Chloramphenicol succinate is an ester prodrug of [chloramphenicol].[A192987] Chloramphenicol is a bacteriostatic antibiotic.

  9. Drug

    Xanomeline

    go.drugbank.com/drugs/DB15357
    ApprovedInvestigational

    [L51713] It is approved as part of a combination product alongside [trospium], a muscarinic antagonist that acts primarily on peripheral muscarinic receptors in order to mitigate the risk and severity … [A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was

  10. Drug

    Dipyrithione

    go.drugbank.com/drugs/DB11327
    Approved

    Dipyrithione, a bactericidal and fungicidal pyrithione derivate, was formulated as Crimanex anti-dandruff shampoo, but is no longer available. … [L2611] It is currently used as a pesticide, and not used in any FDA approved drug products.